Filing Flows › Health Care › Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics (BOLT) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · Bolt Biotherapeutics (BOLT) Q2 2026 earnings results →
Q2 2026 Revenue down 100% year over year to $5K
Bolt Biotherapeutics made $5K in Q2 2026 (-100% Y/Y). Operating margin n/m, net loss $7.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $5K in Q2 2026, down 100% year over year and down 81% from the previous quarter.
Operating costs exceeded revenue by $8.4M, an operating margin of -167480.0%. Total costs fell 24% while revenue fell 100%. The quarter ended with a net loss of $7.7M, wider than the previous quarter's $7.2M loss.
Operating cash flow was −$6.5M. Non-cash charges added back $171K of depreciation and amortization and $552K of share-based compensation. Working capital and other items added $457K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $5K | -100% | n/m | −$7.7M | −$6.5M |
| Q1 2026 | 10-Q | May 12, 2026 | $26K | -98% | n/m | −$7.2M | −$8.0M |
| Q4 2025 | 10-K | Mar 12, 2026 | $2.5M | — | -283.4% | −$6.6M | −$7.2M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $2.2M | +90% | -355.1% | −$7.1M | −$9.7M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $1.8M | +42% | -510.5% | −$8.6M | −$9.6M |
| Q1 2025 | 10-Q | May 12, 2025 | $1.2M | -77% | -991.4% | −$11.0M | −$13.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Bolt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline reflects the Company’s expertise in myeloid biology and cancer drug development. The Company’s lead program is BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1/2 trial that includes patients with gastric and gastroesophageal cancer. The Company has strategic collaborations with Genmab and Toray built around the Company’s Boltbody™ ISAC platform technology. The rest of the Company’s pipeline is currently on hold, including BDC-3042, a Dectin-2 agonist that completed a first-in-human Phase 1 dose escalation trial, as well as its preclinical ISAC programs targeting CEA and PD-L1.
In its own words, from its 8-K, filed Aug 11, 2026.
Bolt Biotherapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -100% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BOLT Bolt Biotherapeutics | Q2 2026 | $5K | -100% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Bolt Biotherapeutics 10-Q on SEC EDGAR · CIK 1641281 · Pharmaceutical Preparations
13F: who owns BOLT and who is buying
More on BOLT
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results